Selexipag

The FDA has approved selexipag for IV use in adults with WHO functional class II to III pulmonary arterial hypertension who are temporarily unable to take oral therapy.

Treatment with selexipag could save payers costs over 2 years compared with oral treprostinil, according to results of a comparative cost model reported at the Academy of Managed Care Pharmacy virtual meeting.

Patients with connective tissue disease-associated pulmonary arterial hypertension benefit from selexipag treatment in the real-world setting, according to new data from the SPHERE analysis.

The Healio editors have compiled a list of recent updates in the management and treatment of pulmonary hypertension.

In patients with newly diagnosed pulmonary arterial hypertension, initial triple oral therapy, compared with double therapy, both improved hemodynamics, NT-proBNP and functional capacity, with no difference between strategies at 26 weeks.